Stockscreener 앱 받기
24.29
0.33%
-0.08
시간 외 거래:
24.29
전일 마감가:
$24.37
열려 있는:
$24.13
하루 거래량:
510.49K
Relative Volume:
0.61
시가총액:
$1.57B
수익:
$32.08M
순이익/손실:
$-169.77M
주가수익비율:
-8.5474
EPS:
-2.8418
순현금흐름:
$-147.70M
1주 성능:
-6.58%
1개월 성능:
-18.52%
6개월 성능:
-28.09%
1년 성능:
-11.06%
1일 변동 폭
$23.95
$24.70
1주일 범위
$23.00
$26.51
52주 변동 폭
$20.32
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
24.29 | 1.60B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-05 | 개시 | Guggenheim | Buy |
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics stock sits 35.28 percent below its high as Bo Cumbo joins board - AD HOC NEWS
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK) - Kalkine Media
A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account. - Stock Titan
Stoke Therapeutics stock reports USD 9.33 million Q2 revenue - AD HOC NEWS
Ruth Walker Appointed Vice President, People & Culture at Stoke Therapeutics - hrtoday.in
Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com India
[Form 3] Stoke Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share. - Stock Titan
Why Is Stoke Therapeutics, Inc. (STOK) Suddenly a Must-Watch Growth Stocks Name? - Kalkine Media
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Stoke Therapeutics, Inc. (STOK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, E - The National Law Review
Stoke Therapeutics appoints Bo Cumbo to board of directors By Investing.com - Investing.com Canada
STOK Looks 163.2% Overvalued on GF Value™ - GuruFocus
Stoke Therapeutics appoints Bo Cumbo to board of directors - Investing.com
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization - Business Wire
Stoke Therapeutics (NASDAQ:STOK) Shares Down 9%What's Next? - MarketBeat
Stoke Therapeutics Appoints Bo Cumbo to Its B - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
News - planetario.buenosaires.gob.ar
Stoke Therapeutics stock holds gains after recent data update - AD HOC NEWS
Stoke Therapeutics, Inc. (STOK) Investor Outlook: Exploring a 60.60% Potential Upside in Biotechnology - DirectorsTalk Interviews
ETFs Investing in Stoke Therapeutics, Inc. Stocks - TradingView
Stoke (STOK) Breaks Out with +4.23% Surge Past $30.54 2026-09-17Zero Lag EMA - siam.in
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)September 16, 2026 - BioSpace
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us
Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Stoke Therapeutics at Cantor conference: dravet data, cash runway - Investing.com
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - The Manila Times
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics grants inducement options to new CSO - scanx.trade
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock gains on Dravet data and Cantor conference plans - ad-hoc-news.de
BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com - Investing.com Nigeria
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Stoke Therapeutics Inc 주식 (STOK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ticho Barry | CHIEF MEDICAL OFFICER |
Oct 01 '26 |
Sale |
26.16 |
1,051 |
27,494 |
19,059 |
0.50%
0.57%
자본화:
|
볼륨(24시간):